3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Methods
5
Surveys and Questionnaires
3
Radiosurgery
3
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
3
Early Intervention, Educational
3
Brachytherapy
3
Biopsy
3
aflibercept
2
Vaccines, Synthetic
2
Vaccines
2
Trastuzumab
2
Sentinel Lymph Node Biopsy
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Papillomavirus Vaccines
2
Palliative Care
2
Counseling
2
Cisplatin
2
tremelimumab
1
tipifarnib
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
fludarabine phosphate
1
fludarabine
1
entinostat
1
durvalumab
1
alovudine
1
aldesleukin
1
Wound Closure Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Vulvar Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled